As noticed, in our current clinical setting, only the wild type treated group showed a statistically significant improvement of FPG, insulinemia, HOMA-IR, ALT, CRP, and TBARS; conversely, the NAFLD wild type control one showed, after 6 months, a worsening of TBARS in comparison to the baseline assessment. Here, CRP is linked to metabolic dysfunction-associated steatotic liver disease.